Fig. 6From: Workflow-driven clinical decision support for personalized oncologyTumour volume time evolution for a tumour treated with bevacizumab according to a treatment scheme consisting of the administration of 15Â mg/kg of bevacizumab as a single-agent, once every three weeks for a total of 4 doses (blue line) and a fractionated version of the aforementioned treatment scheme consisting of the administration of 10Â mg/kg of bevacizumab as a single-agent, every other week for a total of 6 doses (green line)Back to article page